Arrowhead Pharmaceuticals reports fiscal 2025 results in Nov. 25 release

Rhea-AI Filing Summary

Arrowhead Pharmaceuticals, Inc. reported that it has announced and commented on its fiscal 2025 financial results for the period ended September 30, 2025. The announcement was made on November 25, 2025.

The company provided these results in a press release that is included as Exhibit 99.1, with an additional Exhibit 104 covering the interactive data for the cover page. The report was signed on behalf of the company by Chief Financial Officer Daniel Apel.

Insights

Equity analyst

Arrowhead disclosed its fiscal 2025 results via a November 25, 2025 press release.

Arrowhead Pharmaceuticals announced and discussed fiscal 2025 financial results for the period ended September 30, 2025, using a press release dated November 25, 2025. This is a standard way for a public company to communicate completed-year performance to the market.

The key financial figures and any commentary on business trends are contained in Exhibit 99.1, which serves as the primary source of detailed results. Without those figures, only the fact of the results announcement can be evaluated, not the performance itself.

For a complete view of Arrowhead’s fiscal 2025 performance, the detailed numbers and narrative in the November 25, 2025 press release and related financial disclosures would need to be reviewed alongside this high-level announcement.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Arrowhead Pharmaceuticals (ARWR) announce on November 25, 2025?

On November 25, 2025, Arrowhead Pharmaceuticals, Inc. announced and commented on its fiscal 2025 financial results for the period ended September 30, 2025.

Which period do Arrowhead Pharmaceuticals' fiscal 2025 results cover?

Arrowhead Pharmaceuticals’ fiscal 2025 results cover the period ended September 30, 2025.

Where can investors find the detailed fiscal 2025 results for Arrowhead Pharmaceuticals (ARWR)?

The detailed fiscal 2025 results and commentary are provided in a press release furnished as Exhibit 99.1.

Who signed the November 25, 2025 report for Arrowhead Pharmaceuticals (ARWR)?

The report was signed on behalf of Arrowhead Pharmaceuticals, Inc. by Daniel Apel, the company’s Chief Financial Officer.

What exhibits were included with Arrowhead Pharmaceuticals' November 25, 2025 disclosure?

Arrowhead included Exhibit 99.1, a press release dated November 25, 2025, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.

Are Arrowhead Pharmaceuticals' fiscal 2025 results deemed filed for liability purposes?

The company states that the information provided, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/25/2025 - 04:10 PM Learn about SEC filing dates

0000879407FALSE00008794072025-11-252025-11-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

November 25, 2025

Date of Report

(Date of earliest event reported)

Arrowhead Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38042

46-0408024

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105

(Address of principal executive offices, including Zip Code)

(626) 304-3400

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

ARWR

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On November 25, 2025, Arrowhead Pharmaceuticals, Inc. announced and commented on its fiscal 2025 financial results for the period ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release, dated November 25, 2025.
104						Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 25, 2025

ARROWHEAD PHARMACEUTICALS, INC.
By:						/s/ Daniel Apel
						Daniel Apel
						Chief Financial Officer